Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling

J. Bendell, S. Ulahannan, M. Koczywas, J. Brahmer, A. Capasso, S. G. Eckhardt, M. Gordon, C. McCoach, M. Nagasaka, K. Ng, J. Pacheco, J. Riess, A. Spira, C. Steuer, R. Dua, S. Chittivelu, S. Masciari, Z. Wang, X. Wang, S. H. Ou

Research output: Contribution to journalArticlepeer-review

3 Scopus citations
Original languageEnglish (US)
Pages (from-to)S8-S9
JournalEuropean Journal of Cancer
StatePublished - Oct 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this